Folic Acid and Poly(ethylene glycol) Decorated Paclitaxel Nanocrystals Exhibit Enhanced Stability and Breast Cancer-Targeting Capability

Jihui Zhao,Jianliang Du,Jun Wang,Na An,Kuan Zhou,Xiaoge Hu,Zhiying Dong,Yu Liu

DOI: https://doi.org/10.1021/acsami.1c00184

2021-03-17

Abstract:In part because of their high drug loading, nanocrystals (NCs) have seen extensive use in drug delivery, particularly for insoluble or poorly soluble drugs. It remains a challenge, however, to prepare stable nanocrystals with tumor-targeting capability. Here, we designed a novel preparation of stable paclitaxel (PTX) nanocrystals with efficient active tumor-targeting properties. PTX NC was prepared using a bottom-up method and modified with both poly(ethylene glycol) (PEG) and folic acid (FA) derivatives using film hydration. The resulting PTX –PEG–FA had a rodlike shape, with hydrodynamic diameters and drug loading values of 201.90 ± 2.92 nm and 31.07 ± 3.41%, respectively. The size of the PTX –PEG–FA was unchanged after 168 h in the presence of plasma, whereas nonmodified paclitaxel nanocrystals (PTX NC) exceeded 600 nm within 12 h under the same conditions. Cellular uptake and cellular growth inhibition experiments in 4T1 breast cancer cells showed the superiority of PTX –PEG–FA over PTX NC or PEGylated paclitaxel nanocrystals without FA modification (PTX –PEG). A pharmacokinetic evaluation in rats revealed that PTX –PEG–FA significantly prolonged the circulation of PTX in the bloodstream, in comparison with PTX NC or Taxol. Tissue distribution and <i>in vivo</i> antitumor studies in 4T1 orthotopic breast cancer-bearing nude mice showed that PTX –PEG–FA significantly increased the intratumor accumulation of PTX and efficiently inhibited tumor growth, in comparison with PTX –PEG, PTX NC, or Taxol. In summary, PTX –PEG–FA showed good potential for breast cancer-targeted delivery for insoluble therapeutics.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.1c00184?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.1c00184</a>.Supplementary methods, materials, and reagents, PEGylation level optimization, FA modification level optimization, HPLC/MS/MS assay, effect of the PEGylation level on PTX –PEG toxicity to 4T1-Luc cells, effect of the FA modification level on PTX –PEG–FA toxicity to 4T1-Luc cells, effect of the FA modification level on PTX –PEG–FA stability, stability of PTX –PEG–FA in PBS, uptake of PTX –PEG–FA by 4T1-Luc cells measured by flow cytometry, and tissue distribution of PTX in 4T1 orthotopic breast cancer-bearing nude mice after a single dose of PTX –PEG–FA delivered by intravenous injection (<a class="ext-link" href="/doi/suppl/10.1021/acsami.1c00184/suppl_file/am1c00184_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

materials science, multidisciplinary,nanoscience & nanotechnology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to improve the stability and tumor - targeting ability of paclitaxel (PTX) nanocrystals. Specifically, paclitaxel is a first - line chemotherapeutic drug widely used in the treatment of breast cancer, but its low solubility and poor selectivity for tumors limit its efficacy. To overcome these drawbacks, researchers designed a new type of paclitaxel nanocrystal (PTX NC), which is modified by polyethylene glycol (PEG) and folic acid (FA) to enhance its stability and active tumor - targeting properties.

### Main problems
1. **Improving the stability of nanocrystals**: Unmodified paclitaxel nanocrystals have poor stability in the blood and are easily captured by the mononuclear phagocyte system (MPS), resulting in reduced drug efficacy. Therefore, a method is needed to improve the stability of nanocrystals in the blood.
2. **Enhancing tumor - targeting ability**: Through surface modification, nanocrystals can actively recognize and enter tumor cells, thereby increasing the accumulation of drugs in tumor tissues and enhancing the anticancer effect.

### Solutions
- **Materials and methods**:
- Paclitaxel nanocrystals were prepared using the bottom - up method.
- Nanocrystals were modified with PEG and FA by film hydration.
- The modified nanocrystals were denoted as PTX NC@lipid - PEG - FA.

- **Experimental results**:
- **Morphology and particle size**: The modified nanocrystals were rod - shaped, with an average particle size of 201.90 ± 2.92 nm and a drug loading of 31.07 ± 3.41%.
- **Stability**: After 168 hours in plasma, the particle size of PTX NC@lipid - PEG - FA did not change significantly, while the particle size of unmodified nanocrystals exceeded 600 nm within 12 hours.
- **Cell uptake and cell growth inhibition experiments**: In 4T1 breast cancer cells, PTX NC@lipid - PEG - FA showed a higher cell uptake rate and stronger cell growth inhibition effect.
- **Pharmacokinetic evaluation**: In rats, PTX NC@lipid - PEG - FA significantly prolonged the circulation time of paclitaxel in the blood compared to PTX NC or Taxol.
- **Tissue distribution and in - vivo antitumor studies**: In a 4T1 orthotopic breast cancer nude mouse model, PTX NC@lipid - PEG - FA significantly increased the drug accumulation in the tumor and effectively inhibited tumor growth.

### Conclusion
Paclitaxel nanocrystals (PTX NC@lipid - PEG - FA) modified by PEG and FA have good stability and active tumor - targeting ability, showing great potential in targeted delivery for breast cancer.